文献速递胸部肿瘤

非小细胞肺癌新辅助化疗后的病理评估:区分腺癌与鳞状细胞癌的重要性及意义

Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.
PubMed 文献 · J Thorac Oncol · 2018-11-29

本研究回顾272例接受新辅助化疗后手术的临床II-III期NSCLC患者(腺癌192例,鳞癌80例),探讨预测生存的最佳残留存活肿瘤百分比 cutoff 是否在腺癌与鳞癌间不同。鳞癌最佳cutoff为10%,腺癌为65%;鳞癌≤10%存活肿瘤为更好肺癌特异性死亡累积发生率(LC-CID)的独立因素,腺癌≤65%存活肿瘤与更好LC-CID和总生存相关。

要点

  • 鳞癌对新辅助化疗的病理缓解优于腺癌(中位存活肿瘤40% vs 60%)。
  • 主要病理缓解(≤10%存活肿瘤)在鳞癌为26%,腺癌为12%。
  • 预测LC-CID的最佳存活肿瘤cutoff:鳞癌10%,腺癌65%。

核心结论

  • 新辅助化疗后预测生存的最佳残留存活肿瘤百分比cutoff在肺腺癌与鳞状细胞癌之间不同。
  • 该发现对切除标本的病理评估有启示,尤其在未来临床试验设计中。

研究设计与样本

  • 回顾272例接受新辅助化疗及手术的临床II-III期NSCLC患者的肿瘤切片(腺癌192例,鳞癌80例)。
  • 采用最大选择秩统计量确定预测肺癌特异性死亡累积发生率(LC-CID)的最佳存活肿瘤百分比cutoff。
  • LC-CID采用竞争风险方法分析;总生存采用Kaplan-Meier法和Cox比例风险分析。

主要发现

  • 鳞癌患者对新辅助化疗的缓解更好:中位存活肿瘤百分比鳞癌40% vs 腺癌60%(p=0.027)。
  • 主要病理缓解(≤10%存活肿瘤)见于26%的鳞癌病例 vs 12%的腺癌病例(p=0.004)。
  • 预测LC-CID的最佳存活肿瘤cutoff:鳞癌为10%,腺癌为65%。
  • 多变量分析中,鳞癌患者存活肿瘤≤10%是更好LC-CID的独立因素(p=0.035)。
  • 腺癌患者存活肿瘤≤65%是更好LC-CID(p=0.033)和总生存(p=0.050)的因素。

关键数值与推荐

  • 主要病理缓解定义为≤10%残留存活肿瘤,原文未区分组织学类型。
  • 鳞癌预测LC-CID的最佳存活肿瘤cutoff为10%;腺癌为65%。

临床怎么用

  • 原文结论指出,该发现对切除标本的病理评估有启示,尤其在未来临床试验设计中。
  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Major pathologic response after neoadjuvant chemotherapy (NAC) for NSCLC has been defined as 10% or less residual viable tumor without distinguishing between histologic types. We sought to investigate whether the optimal cutoff percentage of residual viable tumor for predicting survival differs between lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC). METHODS: Tumor slides from 272 patients treated with NAC and surgery for clinical stage II-III NSCLC (ADC, n = 192; SCC, n = 80) were reviewed. The optimal cutoff percentage of viable tumor for predicting lung cancer-specific cumulative incidence of death (LC-CID) was determined using maximally selected rank statistics. LC-CID was analyzed using a competing-risks approach. Overall survival was evaluated using Kaplan-Meier methods and Cox proportional hazard analysis. RESULTS: Patients with SCC had a better response to NAC (median percentage of viable tumor: SCC versus ADC, 40% versus 60%; p = 0.027). Major pathologic response (≤10% viable tumor) was observed in 26% of SCC cases versus 12% of ADC cases (p = 0.004). The optimal cutoff percentage of viable tumor for LC-CID was 10% for SCC and 65% for ADC. On multivariable analysis, viable tumor 10% or less was an independent factor for better LC-CID (p = 0.035) in patients with SCC; in patients with ADC, viable tumor 65% or less was a factor for better LC-CID (p = 0.033) and overall survival (p = 0.050). CONCLUSIONS: In response to NAC, the optimal cutoff percentage of viable tumor for predicting survival differs between ADC and SCC. Our findings have implications for the pathologic assessment of resected specimens, especially in upcoming clinical trials design.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Qu Y, Emoto K, Eguchi T, et al. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. J Thorac Oncol. 2018. PMID: 30503889. doi:10.1016/j.jtho.2018.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。